35% of acute cases and 73% of non-hospitalized convalescent COVID-19 cases fulfilled the ADIM 3 group criteria of successful SARS-CoV-2-specific neutralizing antibody, CD4+ T cell, and CD8+ T cell responses. The gene discussed is CD8A; the disease is COVID-19.